10x Genomics, Inc. ($TXG) Stock Forecast: Up 7.6% Today

What is 10x Genomics, Inc.?

10x Genomics (TXG) is a life science company listed on the NASDAQ. The company specializes in providing innovative solutions for single-cell and spatial genomics research.

Why is 10x Genomics, Inc. going up?

TXG stock is up 7.6% on Feb 14, 2025 14:52

• Despite posting a Q4 loss and missing EPS estimates, 10x Genomics (TXG) had a strong bullish movement, indicating that investors are focusing on other positive aspects of the company.
• The company's revenue exceeding estimates could have contributed to the bullish movement, showing potential growth opportunities and market confidence in its products and services.
• The market might be optimistic about 10x Genomics' future prospects, especially with its 2025 sales guidance, even though it falls slightly below consensus, suggesting long-term growth potential.
• Investors may be overlooking short-term profitability concerns and focusing more on the company's revenue performance and strategic direction, driving the bullish movement in the stock.

TXG Price Chart

TXG Technical Analysis

TXG News

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties - 10x Genomics ( NASDAQ:TXG )

10x Genomics posted a Q4 EPS loss of $ ( 0.40 ) , missing the $ ( 0.30 ) estimate. The company's 2025 sales guidance of $610M-$630M is below the $631.14M consensus. Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and ...

https://www.benzinga.com/general/health-care/25/02/43709876/life-science-company-10x-genomics-struggles-with-profitability-analyst-says-2025-guidance-bak

10x Genomics ( TXG ) Reports Q4 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2414936/10x-genomics-txg-reports-q4-loss-tops-revenue-estimates

Seeking Clues to 10x Genomics ( TXG ) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

https://www.zacks.com/stock/news/2413508/seeking-clues-to-10x-genomics-txg-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics

Trending Today

Movement ($MOVE) Crypto Forecast: Up 5.1% Today

MANTRA ($OM) Crypto Forecast: Up 5.3% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Up 5.0% Today

Memecoin ($MEME) Crypto Forecast: Up 9.2% Today

Toncoin ($TON) Crypto Forecast: Up 5.0% Today

Pepe ($PEPE) Crypto Forecast: Up 6.4% Today

dogwifhat ($WIF) Crypto Forecast: Up 9.8% Today

Jupiter ($JUP) Crypto Forecast: Up 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.3% Today

10x Genomics, Inc. Price History

11.09.2024 - TXG Stock was up 12.0%

• Despite Q3 sales underperforming, the CEO's positive outlook on future opportunities potentially boosted investor confidence in 10x Genomics' long-term growth.
• Speculations suggest that Ark Invest's shift away from Moderna Inc. may have prompted some investors to consider alternative biotech companies like 10x Genomics, influencing the stock's rise.
• The general bullish market sentiment included optimism towards firms with growth potential in genomic technology, increasing the demand for 10x Genomics shares.

30.09.2024 - TXG Stock was up 5.8%

• Despite a decrease in instrument sales affecting Q3 earnings, TXG experienced a significant bullish surge today.
• Investor sentiment may be buoyed by the potential for growth in consumable sales, which helped mitigate the drop in instrument sales.
• The market appears to appreciate the company's emphasis on consumables as a more reliable source of revenue compared to instrument sales.
• This uptick in activity could suggest that investors have confidence in 10x Genomics' capability to overcome obstacles and expand into new revenue streams.

11.09.2024 - TXG Stock was up 5.4%

• TXG stock faced a decline after the Q3 sales results were below expectations, disappointing investors.
• The lackluster performance in Q3 may have raised concerns about the company's future growth and its ability to meet market forecasts.
• The decision by Ark Invest to sell off Moderna stock, despite positive post-COVID plans, likely added to a sense of caution in the biotech sector, impacting companies like 10x Genomics.
• In sum, the blend of TXG's financial results and the broader market dynamics probably contributed to the stock's downward movement today.

27.07.2024 - TXG Stock was down 5.0%

• TXG's stock decline may be linked to the CEO and executive's share sales, potentially signaling doubts about the company's future performance and unsettling investors.
• The considerable share volumes offloaded by top management raise concerns about TXG's growth potential and forthcoming financial outcomes, fostering negative investor sentiment.
• While executives may sell company stock for personal financial reasons or diversification, these actions have likely contributed to the current downward pressure on TXG's stock price.

10.09.2024 - TXG Stock was down 27.1%

• TXG stock experienced a bearish movement as the company's Q3 sales fell short of expectations, indicating a potential lack of strong revenue growth.
• The CEO's optimistic outlook for future opportunities may have reassured investors, but the initial disappointment in the sales figures likely contributed to the downward pressure on the stock.
• The market may be reacting to the uncertainty surrounding 10x Genomics' financial performance, leading to a sell-off as investors reevaluate their positions in the company.

31.09.2024 - TXG Stock was down 3.8%

• Despite a loss in the third quarter, 10x Genomics (TXG) exceeded market expectations for earnings per share, potentially triggering a positive market sentiment initially.
• Nevertheless, a drop in instrument sales for the gene sequencing technology in the third quarter resulted in a negative trend for TXG stock, raising concerns among investors regarding revenue growth prospects.
• The conflicting outcomes of surpassing earnings expectations while encountering a decrease in sales underscored the market's emphasis on revenue generation and future growth potential for 10x Genomics, leading to the downward movement in the stock price.

05.01.2025 - TXG Stock was up 5.7%

• Despite worries about negative earnings expectations, 10x Genomics (TXG) surprised the market with a strong bullish performance, indicating positive investor sentiment.
• Trades by Ark Invest, led by Cathie Wood, did not directly impact 10x Genomics (TXG) stock, allowing it to stand out positively in today's market.
• The bullish movement in 10x Genomics (TXG) stock may be linked to favorable internal developments, suggesting potential positive upcoming earnings despite initial apprehensions.

13.07.2024 - TXG Stock was up 5.6%

• The uptrend in TXG stock today may be linked to a notable acquisition by Catherine Wood, boosting investor confidence in the company's future.
• Despite revising its 2024 guidance amid macro pressures, the market appears to view the company's adaptability positively.
• The recent appointment of Adam Taich as CFO could also be enhancing the optimistic outlook for TXG, suggesting potential strategic growth changes within the company.
• Positive sentiment towards gene editing stocks and the promise of medical advancements has likely contributed to the bullish momentum in 10x Genomics, with investors eyeing long-term growth opportunities in this sector.

09.07.2024 - TXG Stock was up 12.5%

• Positive earnings and revenue surprises in the recent financial report boosted TXG stock today.
• The company's adjustment in its 2024 guidance due to macro pressures was well-received by investors, showcasing its adaptability.
• The appointment of new CFO Adam Taich inspired confidence in the company's leadership and financial strategies.
• The optimistic outlook on gene editing stocks and market growth potential in the sector have fueled positive investor sentiment towards TXG.

09.07.2024 - TXG Stock was up 7.3%

• The appointment of Adam Taich as the new CFO could have instilled confidence in investors, signaling potential positive strategic changes within the company.
• Despite reporting a loss in the second quarter, the fact that 10x Genomics topped revenue estimates could have reassured investors about the company's growth potential.
• The strong bullish movement in TXG's stock today might be attributed to the positive earnings surprise of 31.91% and revenue beat of 1.46% in the second quarter, indicating a strong performance and potential future growth.
• Wall Street estimates and projections for key metrics also likely played a role in boosting investor sentiment and driving the bullish movement in TXG's stock.

14.01.2025 - TXG Stock was up 7.6%

• Despite posting a Q4 loss and missing EPS estimates, 10x Genomics (TXG) had a strong bullish movement, indicating that investors are focusing on other positive aspects of the company.
• The company's revenue exceeding estimates could have contributed to the bullish movement, showing potential growth opportunities and market confidence in its products and services.
• The market might be optimistic about 10x Genomics' future prospects, especially with its 2025 sales guidance, even though it falls slightly below consensus, suggesting long-term growth potential.
• Investors may be overlooking short-term profitability concerns and focusing more on the company's revenue performance and strategic direction, driving the bullish movement in the stock.

13.01.2025 - TXG Stock was down 5.7%

• TXG reported a Q4 loss, which was lower than expected by 25%.
• Despite topping revenue estimates slightly, the market reacted negatively to the earnings miss.
• Investors might be concerned about the company's future performance and profitability, leading to the bearish movement in the stock price.
• The market sentiment towards TXG seems to be influenced by the disappointing earnings report, causing a sell-off in the stock.